Clinical Trial: A Study to Evaluate ALN-6222 in Participants With Obesity

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07624071) titled 'A Study to Evaluate ALN-6222 in Participants With Obesity' on May 29.

Brief Summary: This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.

Study Start Date: June 03

Study Type: INTERVENTIONAL

Condition: Obesity

Intervention: DRUG: ALN-6222

ALN-6222 will be administered subcutaneously (SC).

DRUG: Placebo

Placebo will be administered SC.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: ...